Loading…
Chinese maker of home medical devices — glucose meters, lancets and disposable diagnostic consumables.
Chinese maker of home medical devices — glucose meters, lancets and disposable diagnostic consumables.
Sells branded home-use devices largely through online shops and pharmacy chains, with marketing and sales channels a major cost. Disposable test strips used with its meters bring repeat purchases.
In one line: A Chinese home-diagnostics device maker.
Moat: none (distribution). Competitive home-diagnostics category with several similar domestic makers.
Headquarters: Zhuhai, Guangdong, China · Employees: 5,081
Size Cofoe Medical Technology (301087.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.71B, the 1457th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥50.45 on 6 Nov 2026.
Performance Over six months the shares fell 4.8%, against +2.4% for the median peer and -16.4% for the China market (cap-weighted) — 8th lowest of 20 in its peer set.
Growth Revenue grew 33.5% over the last twelve months (peer median +9.3%); the operating margin is 9.9% (peer median 12.7%).
Valuation It trades at 26.9× forward earnings against a peer median of 26.2× (9th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.6 points above its cost of capital (9.1% WACC).
Next results Next results expected around 4 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.18B | CN¥3.37B | CN¥2.98B | CN¥2.84B | CN¥2.97B |
| Revenue growth | — | +13% | +5% | -4% | — |
| Gross profit | CN¥2.37B | CN¥1.65B | CN¥1.42B | CN¥1.12B | CN¥1.09B |
| EBITDA | n/a | CN¥528M | CN¥491M | CN¥366M | CN¥376M |
| Net income | CN¥417M | CN¥372M | CN¥312M | CN¥254M | CN¥302M |
| Free cash flow | CN¥259M | CN¥557M | CN¥557M | CN¥64.2M | -CN¥478M |
| Capital expenditure | CN¥141M | CN¥178M | CN¥120M | CN¥373M | CN¥640M |
| Total debt | CN¥1.33B | CN¥917M | CN¥1.00B | CN¥744M | CN¥577M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Cofoe Medical Technology 301087.SZ | $1.71B | -5% | +33% | 10% | 26.9× | 12.5% |
| Sinocare 300298.SZ | $1.58B | +15% | +7% | 6% | 23.6× | 10.8% |
| Andon Health 002432.SZ | $3.60B | -29% | -30% | -26% | 15.0× | -7.7% |
| Jiangsu Yuyue Medical Equipment & Supply 002223.SZ | $4.26B | -1% | -1% | 13% | 20.4× | 5.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301087.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.5% | +1.1% | 7th lowest of 21 |
| 6-month return | -4.8% | +2.4% | 8th lowest of 20 |
| Distance from 52-week high | -21.2% | -22.1% | 10th highest of 21 |
| Revenue growth (TTM) | +33.5% | +9.3% | 6th highest of 21 |
| Operating margin | 9.9% | 12.7% | 10th lowest of 21 |
| Forward P/E | 26.9× | 26.2× | 9th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 12.5% | 10.8% | 7th most demanding of 14 |
| Growth delivered (Del g) | +7.4% | +14.5% | 4th lowest of 14 |
| Hurdle (Req g minus delivered) | +5.1 pp | -7.5 pp | 3rd most demanding of 14 |
| ROIC minus cost of capital | +2.6 pp | +0.6 pp | 8th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cofoe Medical Technology 301087.SZ | China | $1.71B | -5% | +33% | 10% | 26.9× | 12.5% | +7.4% |
| Kestra Medical Technologies KMTS | United States | $1.72B | +37% | +61% | -134% | n/a | n/a | n/a |
| Butterfly Network BFLY | United States | $1.70B | +53% | +39% | -36% | n/a | n/a | n/a |
| Poly Medicure POLYMED.NS | India | $1.73B | -4% | +18% | 17% | 40.6× | n/a | n/a |
| Angelalign Technology 6699.HK | Hong Kong | $1.74B | -7% | +84% | 9% | 52.1× | 18.1% | +25.8% |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.69B | +124% | +3% | 49% | 52.0× | 17.9% | +12.7% |
| Embla Medical hf EMBLA.CO | Denmark | $1.75B | +3% | +6% | 14% | 17.9× | -1.8% | +8.3% |
| Fukuda Denshi 6960.T | Japan | $1.75B | -5% | 0% | 19% | 14.6× | -3.2% | -1.0% |
| Rigaku 268A.T | Japan | $1.66B | -57% | +5% | 15% | 20.4× | 18.8% | +14.5% |
| Molbio Diagnostics MOLBIO.NS | India | $1.63B | n/a | +35% | 17% | n/a | n/a | n/a |
| Wuxi Unicomp Technology 688531.SS | China | $1.80B | -36% | +53% | 12% | 40.7× | n/a | n/a |
| Vitrolife VITR.ST | Sweden | $1.63B | +14% | -2% | 19% | 27.6× | 22.0% | +22.5% |
| Nihon Kohden 6849.T | Japan | $1.63B | +8% | +1% | 7% | 17.6× | -2.1% | +3.3% |
| Medartis MED.SW | Switzerland | $1.83B | +47% | +30% | 2% | 74.2× | n/a | n/a |
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.59B | -14% | +16% | 44% | 17.2× | 3.1% | +23.4% |
| Inner Mongolia Furui Medical Science 300049.SZ | China | $1.85B | -5% | +11% | 25% | 53.2× | 6.6% | +14.6% |
| LeMaitre Vascular LMAT | United States | $1.85B | -25% | +12% | 29% | 26.2× | 2.9% | +14.0% |
| Sinocare 300298.SZ | China | $1.58B | +15% | +7% | 6% | 23.6× | 10.8% | +18.3% |
| Inspire Medical Systems INSP | United States | $1.85B | +45% | 0% | 2% | 45.4× | 30.9% | +51.2% |
| Enovis ENOV | United States | $1.57B | +2% | +5% | 3% | 7.7× | 22.3% | -6.0% |
| NIPRO 8086.T | Japan | $1.55B | -9% | +3% | 6% | 14.9× | n/a | n/a |